Huntington National Bank’s Pacira BioSciences PCRX Stock Holding History

Huntington National Bank’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.35K	Buy	148 +117	+377%	+$2.6K	﹤0.01%	2165
2025 Q4	$802	Sell	31 -22	-42%	-$523	﹤0.01%	2299
2025 Q3	$1.37K	Hold	53	–	–	﹤0.01%	2261
2025 Q2	$1.27K	Hold	53	–	–	﹤0.01%	2302
2025 Q1	$1.32K	Hold	53	–	–	﹤0.01%	2322
2024 Q4	$998	Buy	53 +31	+141%	+$544	﹤0.01%	2387
2024 Q3	$331	Sell	22 -111	-83%	-$1.9K	﹤0.01%	2563
2024 Q2	$3.81K	Sell	133 -47	-26%	-$1.34K	﹤0.01%	1984
2024 Q1	$5.26K	Buy	180 +110	+157%	+$3.38K	﹤0.01%	1902
2023 Q4	$2.36K	Buy	70 +55	+367%	+$1.61K	﹤0.01%	2052
2023 Q3	$460	Sell	15 -34	-69%	-$1.23K	﹤0.01%	2275
2023 Q2	$1.96K	Buy	49 +33	+206%	+$1.36K	﹤0.01%	2027
2023 Q1	$653	Buy	16 +5	+45%	+$199	﹤0.01%	2070
2022 Q4	$425	Sell	11 -1	-8%	-$49	﹤0.01%	1945
2022 Q3	$0	Buy	12 +1	+9%	+$56	﹤0.01%	2296
2022 Q2	$0	Hold	11	–	–	﹤0.01%	2319
2022 Q1	$0	Hold	11	–	–	﹤0.01%	2278
2021 Q4	$0	Hold	11	–	–	﹤0.01%	2232
2021 Q3	$0	Buy	+11	New	+$634	﹤0.01%	1973

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Huntington National Bank's PCRX Position: Q1 2026 in Review

Huntington National Bank increased its Pacira BioSciences (PCRX) stake by 377% in Q1 2026, buying an estimated $2.6K and bringing the position to 148 shares worth $3.35K. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

Huntington National Bank first reported a position in PCRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $5.26K in Q1 2024. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Huntington National Bank held 148 shares of Pacira BioSciences worth $3.35K as of Q1 2026.
Huntington National Bank bought 117 Pacira BioSciences shares in Q1 2026, an estimated $2.6K.
Pacira BioSciences made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #2165 holding.
Huntington National Bank first reported a position in Pacira BioSciences in Q3 2021 and has held it in 19 quarters since.
Huntington National Bank's Pacira BioSciences position peaked at $5.26K in Q1 2024.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.